Together, these findings indicated that the decrease in PARP1 expression because of the rs907187‐G allele may predispose NB patients to better response to induction therapy and support a potential role of PARP1 as a candidate gene in therapeutic failure of NB treatment. This evidence concerns the gene PARP1 and neuroblastoma.